Treatment of sweet's syndrome with the tumor necrosis factor antagonist etanercept in a patient with coexisting rheumatoid arthritis - 21/08/11
Vivian Gindi, MD, Nicholas Lowe, MD, Clinical Research Specialists, Santa Monica, CA, United States; Supin Koo, PhD, Amgen, Thousand Oaks, CA, United States; Paul Yamauchi, MD, PhD, Clinical Research Specialists, Santa Monica, CA, United States
Le texte complet de cet article est disponible en PDF. P2815 Dr. Gindi has no conflicts of interest to disclose. Dr. Lowe is a member of the speakers bureau for Amgen, Inc. Dr. Yamauchi is a consultant, principal investigator, and speaker for Amgen, Inc., but has no proprietary interest in the company. Writing support and poster production provided by Immunex Corporation, a wholly owned subsidiary of Amgen, Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P200 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?